ATAGI have released new guidance for healthcare providers ​regarding the administration of Japanese encephalitis virus (JEV) vaccines.​ These recommendations follow on from earlier advice from CDNA identifying the groups at highest risk of disease and who should be prioritised for vaccination.

The guidance includes:

  • vaccine brand and dosing recommendations
  • priority populations
  • advice for women who are pregnant or breastfeeding
  • booster doses
  • co-administration with other vaccines
  • ​common and expected side effects following vaccination

To read the ATAGI recommendations in full, please click on the link below:
ATAGI clinical guidance on Japanese encephalitis virus vaccines

For further information on JEV, including background on disease and common vaccine questions, please click on the link below: